leisure time -WSS

leisure time

author：entertainment 2025-08-14 19:22:36 - browse：13

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Hospital price transparency does save money, advocate argues

hotspot

WSS

Solve the antibiotic resistance crisis with preventive drugs

Medicare reduced heart disease by changing how it pays doctors

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

STAT Summit: Biotech founders on deal

Home health providers sue Medicare over payment cuts

Will Ozempic

hotspot

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

entertainment

The high cost of giving birth even with insurance

Will Ozempic

ChatGPT in medicine: STAT answers readers' burning questions

Solve the antibiotic resistance crisis with preventive drugs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Summit: How a Chicago ER doctor tackles gun violence

Tori Bowie and the unacceptable rates of Black maternal death

The explosion of genetic testing requires a new approach

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hospital price transparency does save money, advocate argues

Wikipedia

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Create a giant ice tray with this foil pan hack to keep food cold this summer

Presidential fundraising highlights so far: Trump brings in more than DeSantis

STAT Readout Newsletter: Today's biggest biotech updates

NIH confirmation hearing shows politicization of research

FDA struggles to regulate food additives, sometimes for decades

knowledge

focus

hotspot

entertainment